GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients

Magnetic Resonance Imaging Clinical Trial

— GARDIAN  

Official title:

GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01095081
• Other study ID #: 14823
• Secondary ID: GV0901
• Status: Completed
• Phase: N/A
• First received: March 17, 2010
• Last updated: January 19, 2015
• Start date: July 2010
• Est. completion date: April 2013

Study information

• Verified date: January 2015
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: Hungary: National Institute of PharmacyChina: Ethics CommitteeSouth Korea: Korea Food and Drug Administration (KFDA)South Africa: Human Research Ethics CommitteeRussia: Federal Service on Survailance in Healthcare and Social DevelopmentKazakhstan: Ethical CommissionKyrgyzstan: Ethical CommissionTaiwan: Institutional Review BoardThailand: Ethical CommitteeFrance: French Data Protection AuthorityItaly: Ethics CommitteePoland: Office for Registration of Medicinal Products, Medical Devices and Biocidal ProductsSpain: Regional Health AuthoritiesBosnia: Federal Ministry of Health
• Study type: Observational

Clinical Trial Summary

Prospective, non-interventional, multi-center study. The observation period for each subject covers the treatment period with Gadovist®. For each patient, the treating physician or nurse documents demographics, medical data, safety parameters and treatment signs and symptoms at the visit. Patients with severe renal impairment will be followed-up after 3 month by phone call from the investigator if in line with routine practice. Data audit/monitoring by source data verification will be done in a subset of sites and patients

Description:

Evaluate the safety and tolerability of Gadovist in patients requiring contrast-enhanced MRI.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23775
• Est. completion date: April 2013
• Est. primary completion date: April 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients undergoing contrast enhanced Magnetic Resonance Imaging with Gadobutrol (Gadovist).

Exclusion Criteria:

• There are no other exclusion criteria beyond the contraindications contained in the Summary of Product Characteristics (hypersensitivity to the active substance or to any of the excipients) and the warnings.

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Magnetic Resonance Angiography
• Magnetic Resonance Imaging

Intervention

Drug:
• Gadobutrol (Gadovist, BAY86-4875)
Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer

Countries where clinical trial is conducted

Bosnia and Herzegovina,  Canada,  China,  Czech Republic,  France,  Germany,  Greece,  Hong Kong,  Hungary,  Italy,  Kazakhstan,  Korea, Republic of,  Kyrgyzstan,  Poland,  Russian Federation,  South Africa,  Spain,  Taiwan,  Thailand,  Vietnam, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Event Collection / Calculation of Adverse Event rates in Study population and subgroups		1 day	Yes
Secondary	Analysis of Adverse Event Collection rates according to age, gender, concomitant diseases and risk factors, dose administered.		1 day	Yes

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
•   Click here to find results for studies related to Bayer Healthcare products.